5
Monozyme
522199 BSE
Monozyme
Healthcare BSE: 522199 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
4- Company has low interest coverage ratio.
- Company has a low return on equity of -24.5% over last 3 years.
- Company has high debtors of 50,127 days.
- Working capital days have increased from 15,794 days to 46,842 days
Growth Rate
Revenue Growth
-99%
Net Income Growth
51%
Quarterly Results
| Particulars | Dec 2024 | Dec 2025 |
|---|---|---|
| Sales | 34.63 | 49.28 |
| Expenses | 25.13 | 37.94 |
| Operating Profit | 9.5 | 11.34 |
| OPM % | 27.43% | 23.01% |
| Other Income | 0.08 | 0.03 |
| Interest | 3.41 | 4.57 |
| Depreciation | 5.29 | 4.6 |
| PBT | 0.88 | 2.2 |
| Tax % | -20.45% | 21.36% |
| Net Profit | 1.06 | 1.74 |
| EPS in Rs | 0.43 | 0.71 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Sales | 10.55 | 4.96 | 0.03 |
| Expenses | 9.63 | 5.62 | 1.95 |
| Operating Profit | 0.92 | -0.66 | -1.92 |
| OPM % | 8.72% | -13.31% | -6400% |
| Other Income | 0.05 | 0.06 | 2.22 |
| Interest | 0.38 | 0.49 | 0.37 |
| Depreciation | 0.08 | 0.13 | 0.1 |
| PBT | 0.51 | -1.22 | -0.17 |
| Tax % | 35.29% | 7.38% | 0% |
| Net Profit | 0.33 | -1.31 | -0.17 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Equity Capital | 3.12 | 3.12 | 3.12 |
| Reserves | -0.23 | -1.54 | -1.71 |
| Borrowings | 5.38 | 4.93 | 2.72 |
| Other Liabilities | 2.96 | 1.49 | 0.72 |
| Total Liabilities | 11.23 | 8 | 4.85 |
| Fixed Assets | 0.71 | 0.59 | 0.4 |
| CWIP | 1.34 | 1.34 | 0 |
| Investments | 0 | 0 | 0 |
| Other Assets | 9.18 | 6.07 | 4.45 |
| Total Assets | 11.23 | 8 | 4.85 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Operating | -1.35 | — | — |
| Investing | -1.02 | — | — |
| Financing | 2.8 | — | — |
| Net Cash Flow | 0.43 | — | — |
| Free Cash Flow | -2.41 | — | — |
| CFO/OP | -127 | — | — |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Debtor Days | 190 | 330 | 50,127 |
| Inventory Days | 155 | 140 | 0 |
| Days Payable | 158 | 52.76 | — |
| Cash Conversion Cycle | 187 | 418 | 50,127 |
| Working Capital Days | 192 | 347 | 46,842 |
| ROCE % | — | -9.88% | -5.08% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Monozyme insights
37 extracted metrics + investor summaries across FY06–FY25.
Documents
1
Outcome of Board Meeting
28 February 2026 - Board approved unaudited standalone results for quarter and nine months ended 31-Dec-2025; limited review attached. 28 February 2026 - Board approved unaudited standalone results for quarter and nine months ended 31-Dec-2025; limited review attached.
2
Statement of deviation(s) or variation(s) under Reg. 32
28 February 2026 - No deviation in utilization of Rs.43.26 crore IPO proceeds for quarter ended Dec 31, 2025. 28 February 2026 - No deviation in utilization of Rs.43.26 crore IPO proceeds for quarter ended Dec 31, 2025.
3
Trading Window
25 February 2026 - Trading window closed from Feb 25, 2026 until 48 hours after unaudited Q3/9M (Dec 31, 2025) results. 25 February 2026 - Trading window closed from Feb 25, 2026 until 48 hours after unaudited Q3/9M (Dec 31, 2025) results.
4
Reply to Clarification- Financial results
4 February 2026 - Clarifies Nov 14, 2025 financial results; no deviation in utilization of Rs.43.26 crore IPO proceeds. 4 February 2026 - Clarifies Nov 14, 2025 financial results; no deviation in utilization of Rs.43.26 crore IPO proceeds.
5
Outcome of Board Meeting
22 January 2026 - Allotment of 80,00,000 shares at Rs114 each; proceeds Rs91.20 crore; issued Jan 22, 2026. 22 January 2026 - Allotment of 80,00,000 shares at Rs114 each; proceeds Rs91.20 crore; issued Jan 22, 2026.
Frequently Asked Questions about Monozyme
What does Monozyme India Ltd do?
Monozyme India Ltd is engaged in Healthcare/Hospitals business.
Where is Monozyme India Ltd (522199) listed?
Monozyme India Ltd trades under code 522199 on the BSE.
Which sector does Monozyme India Ltd belong to?
Monozyme India Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Monozyme India Ltd is engaged in Healthcare/Hospitals business.
Website monozyme.com
Face Value ₹ 5
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/522199.md for Monozyme India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.